Focused On-demand Library for tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UET6

UPID:

TRM7_HUMAN

Alternative names:

2'-O-ribose RNA methyltransferase TRM7 homolog; Protein ftsJ homolog 1

Alternative UPACC:

Q9UET6; B2RCJ0; O75670

Background:

The tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase, also known as 2'-O-ribose RNA methyltransferase TRM7 homolog or Protein ftsJ homolog 1, plays a crucial role in the methylation of the 2'-O-ribose of nucleotides in tRNA anticodon loops. This modification is essential for accurate cytoplasmic translation, impacting translation efficiency, neurogenesis, mitochondrial translation, energy generation, and lipid biosynthesis. The protein's interaction with THADA and WDR6 is necessary for its function.

Therapeutic significance:

Given its involvement in Intellectual developmental disorder, X-linked 9, understanding the role of tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase could open doors to potential therapeutic strategies for treating intellectual developmental disorders and enhancing neurogenesis.